Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and sodium hyaluronate (HA) manufacturing. This Form 10-Q covers the fiscal quarter ended August 25, 2024. The Company operates as a single reportable segment and is classified as an Accelerated Filer and Smaller Reporting Company.
Key Financial Metrics
| Metric | Q1 2025 (Ended Aug 25, 2024) | Q1 2024 (Ended Aug 27, 2023) |
|---|---|---|
| Total Revenues | $24.7 million | $24.5 million |
| Gross Profit | $5.4 million | $2.7 million |
| Gross Margin | 21.8% | 11.1% |
| Operating Loss | $(11.6) million | $(8.6) million |
| Net Loss | $(16.2) million | $(10.8) million |
| Diluted Loss Per Share | $(0.53) | $(0.35) |
| Cash and Cash Equivalents | $5.5 million | $8.6 million (End of Period) |
| Net Cash Used in Operating Activities | $(0.6) million | $(8.3) million |
| Total Debt (Principal) | $168.2 million | $164.5 million |
| Revolving Credit Facility Availability | $4.5 million | N/A |
Material Changes vs. Prior Period
- Revenue Stability: Total revenue increased slightly by 1% ($183,000). This was driven by a $1.5 million increase in HA manufacturing revenue due to shipment timing, partially offset by a $1.3 million decrease in CDMO revenue as a customer worked down inventory.
- Gross Margin Expansion: Gross profit increased 97% to $5.4 million, with margins improving from 11.1% to 21.8%. This was primarily due to favorable sales mix and price increases in CDMO services, partially offset by inventory write-downs in HA manufacturing.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses surged 61% to $14.8 million. This increase was largely driven by non-recurring professional fees of $4.7 million, including $2.4 million in audit fees (due to an auditor switch) and $2.3 million in legal fees related to civil litigation and a stockholder activist settlement.
- Interest Expense: Net interest expense increased 36% to $5.4 million, primarily due to amortization of debt discounts on the Alcon term loan and reduced capitalized interest.
- Discontinued Operations: The prior year period included $1.9 million of income from discontinued operations (Curation Foods insurance settlement), which was absent in the current period.
Outlook, Risks, and Unusual Items
- Liquidity and Capital Resources: Cash decreased by $2.9 million during the quarter. The Company has approximately $4.5 million available under its Revolving Credit Facility. Management believes existing cash, operating cash flow, and a subsequent equity offering (see below) will fund operations for at least 12 months.
- Subsequent Equity Offering: On October 3, 2024, the Company closed a Securities Purchase Agreement to sell approximately 5.9 million shares of common stock for gross proceeds of approximately $24.3 million ($4.10 per share).
- Legal and Regulatory Risks:
- SEC Subpoena: The Company is responding to an SEC subpoena issued in February 2024 regarding a financial statement restatement.
- Internal Controls: Disclosure controls and procedures were deemed not effective as of August 25, 2024, due to material weaknesses in internal control over financial reporting. Remediation plans are underway.
- Registration Rights Penalties: The Company incurred $275,000 in monetary penalties and $95,000 in interest for delinquent SEC filings under the Registration Rights Agreement.
- Landlord Disputes: Ongoing civil actions regarding unpaid rent for former Curation Foods properties.
- Debt Derivative Liability: A gain of $0.9 million was recognized from the change in fair value of a debt derivative liability related to the Alcon term loan.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $24.3 million proceeds from the October 2024 equity offering combined with the $4.5 million revolver availability to cover the high burn rate and debt service obligations.
- Debt Covenants: Confirm continued compliance with financial covenants under the Term Loan and Revolving Credit Facility, given the high effective interest rate (22.5% on Term Loan).
- Internal Control Remediation: Monitor the progress of remediation for material weaknesses in internal controls, as this impacts the reliability of future financial reporting.
- Legal Exposure: Assess the potential financial impact of the SEC investigation, the Yucatan Foods litigation, and landlord disputes, noting that ultimate outcomes are uncertain.
- Customer Concentration: Review the dependency on top customers, as two customers accounted for 32% and 24% of revenue in the quarter.